GAMMA Investing LLC Increases Holdings in Haleon plc (NYSE:HLN)

GAMMA Investing LLC raised its holdings in Haleon plc (NYSE:HLN - Free Report) by 969.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 227,358 shares of the company's stock after purchasing an additional 206,100 shares during the quarter. GAMMA Investing LLC's holdings in Haleon were worth $22,095,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Sierra Ocean LLC bought a new stake in shares of Haleon during the 4th quarter valued at approximately $26,000. Spire Wealth Management bought a new stake in shares of Haleon in the 4th quarter valued at $39,000. FIL Ltd boosted its position in Haleon by 45.7% during the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the last quarter. Addison Advisors LLC raised its position in shares of Haleon by 28.7% in the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after acquiring an additional 1,106 shares in the last quarter. Finally, Mather Group LLC. lifted its stake in shares of Haleon by 177.4% in the 4th quarter. Mather Group LLC. now owns 5,623 shares of the company's stock valued at $54,000 after purchasing an additional 3,596 shares during the period. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Stock Down 0.4%

HLN traded down $0.05 during mid-day trading on Friday, reaching $11.07. 13,897,070 shares of the stock were exchanged, compared to its average volume of 8,708,230. The company has a 50 day moving average price of $10.48 and a two-hundred day moving average price of $10.02. The stock has a market capitalization of $49.84 billion, a PE ratio of 32.56, a price-to-earnings-growth ratio of 2.82 and a beta of 0.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a 1 year low of $8.25 and a 1 year high of $11.42.

Analysts Set New Price Targets

Several research firms recently commented on HLN. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. HSBC reaffirmed a "hold" rating on shares of Haleon in a research note on Wednesday, March 5th. Barclays reissued an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Wall Street Zen cut Haleon from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Six research analysts have rated the stock with a hold rating, four have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.